Board of Directors
Bruce Booth, DPhil
Bruce Booth is a partner at Atlas Venture and focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. Bruce is currently chairman of the board of directors of miRagen Therapeutics, Nimbus Therapeutics, Rodin Therapeutics, and Quartet Medicine, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapetics, Unum Therapeutics, and Zafgen (NASDAQ:ZFGN). He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), and a number of other ventures. Bruce serves as an advisor in various capacities to UCB Pharma, Shire, Pfizer, and Takeda. He also serves on the board of the National Venture Capital Association. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology. Prior to joining Atlas in 2005, Bruce was a principal for Caxton Health Holdings, as well a consultant at McKinsey & Company. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.
Geoff is an experienced CEO with proven success leading innovative businesses. While CEO of Organogenesis Inc., the company treated 1 million patients with living cell therapies, received the first FDA CBER allogeneic cell-therapy approval and achieved an unparalleled position within regenerative medicine. Geoff was founding CEO of eGenesis, applying CRISPR Cas-9 gene editing to xenotransplantation. Geoff spent 11 years at Novartis in senior leadership positions within the Global Transplantation & Immunology franchise. Past activities include Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, and Advisory Council to the Health Policy Commission for Massachusetts. Through his public and private enterprise work, Geoff is dedicated to applying innovation to reshape and improve the quality of healthcare.
Ian is currently serving as an Operating Partner within Clarus Ventures and most recently served as Chief Executive Officer and Head of North American Commercial Operations at Genentech. From 2003 to 2010 he held the positions of Head of Global Product Strategy and Chief Marketing Officer of Roche, Executive Vice President – Commercial Operations and Senior Vice President and General Manager – BioOncology at Genentech. Prior to joining Genentech, he served as general manager of Novartis Canada, where he oversaw all of the company’s country operations, and as Chief Operating Officer for Novartis United Kingdom. Ian serves on the boards of Agios Pharmaceuticals, Inc., Corvus Pharmaceuticals, Inc., and Shire plc. He was recently a member of the Kite Pharma board until its acquisition by Gilead Inc. He has served on the board of directors of the Biotechnology Industry Organization (BIO) since 2009, as well as on the boards of TerraVia and the Gladstone Foundation, and as a member of the Federal Reserve Bank of San Francisco’s Economic Advisory Council. He is an Advisor to the Institute of Life Sciences at Southampton University in the UK. Ian received a Bachelor of Science Degree and an Honorary Doctorate in Biological Sciences from Southampton University in the United Kingdom.
Annalisa Jenkins, MBBS, FRCP
Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. She has recent experience in the fields of gene therapy and rare disease, having served as president and CEO of Dimension Therapeutics, Inc., until its acquisition in November 2017. Her prior leadership roles at global pharmaceutical companies included serving as executive vice president, global development and medical for Merck Serono, and several senior positions at Bristol-Myers Squibb spanning 15 years including as a senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Currently, Dr. Jenkins chairs the boards of CellMedica, Cocoon, Vium, Inc., and Silence Therapeutics; serves as chief executive advisor to PlaqueTec Ltd.; and is a director on the boards of Ardelyx, Oncimmune Holdings plc, and a number of early–stage private biotech and life science companies. She also serves as a committee member of the Science Board to the U.S. Food and Drug Administration (FDA). Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.
Scott Requadt, JD, MBA
Scott Requadt, JD, MBA, is currently a Managing Director at Clarus. Scott has over 17 years of operating and investment experience in the pharmaceutical industry, spanning therapeutics and medtech, and also currently serves on the Boards of VBI Vaccines (Nasdaq: VBIV), ESSA Pharmaceuticals (Nasdaq: EPIX) and two privately-held structured finance vehicles. Prior board and observer roles include TYRX (acquired by Medtronic), Oxford Immunotec (Nasdaq: OXFD), Catabasis (Nasdaq: CATB), Biolex Therapeutics and LINK Medicine (acquired by AstraZeneca). Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals until it was acquired by Johnson & Johnson. Prior to TransForm, Scott practiced as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Before that, Scott was a law clerk at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance) from McGill University (First Class Honors), a law degree from University of Toronto and an MBA from Harvard Business School (Baker Scholar).
Joshua Resnick, MD, MBA
Josh is a highly-regarded life sciences leader, entrepreneur, and investment professional with more than 15 years of experience in investing, company formation, and company leadership across all stages from discovery through commercialization. Before joining SVLS, Dr. Resnick was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund that he established, built and managed within Merck & Co. Prior to MRL Ventures, Dr. Resnick was a Venture Partner with Atlas Venture, focusing on company formation, seed and Series A investing. During his tenure at Atlas, Dr. Resnick was also the Founder and CEO of two start-ups in the immuno-oncology and neuro spaces. Prior to Atlas Venture, Dr. Resnick was a Partner at Prism Venture Partners, where he focused on early-stage biopharmaceutical, medical device, tools and diagnostics investments. Dr. Resnick is also an Attending Physician at Massachusetts General Hospital as well as Brigham and Women’s Hospital, and an Instructor in Medicine at Harvard Medical School. Dr. Resnick graduated Magna Cum Laude from Williams College and received his MD and MBA from the University of Pennsylvania School of Medicine and Wharton School of Business.
Christopher Paige, PhD, FCAHS
Christopher earned a PhD in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. He became a Member of the Basel Institute for Immunology in Switzerland in 1980 where he worked until joining the Ontario Cancer Institute as a Senior Scientist in 1987. In 1990, Dr Paige became the founding Director of the Arthritis and Autoimmunity Research Centre as well as Director of Research at The Wellesley Hospital. In 1997, he returned to OCI, now part of the University Health Network, to assume the role of Vice President, Research at UHN. Dr Paige now serves as Senior Scientist at UHN and is a Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto.